The Follicular Thyroid Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Follicular Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Follicular Thyroid Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Follicular Thyroid Cancer and features dormant and discontinued products.
GlobalData tracks 22 drugs in development for Follicular Thyroid Cancer by 18 companies/universities/institutes. The top development phase for Follicular Thyroid Cancer is phase ii with 14 drugs in that stage. The Follicular Thyroid Cancer pipeline has 22 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Follicular Thyroid Cancer pipeline products market are: AstraZeneca, Jiangsu Hengrui Medicine and Novartis.
The key targets in the Follicular Thyroid Cancer pipeline products market include Vascular Endothelial Growth Factor Receptor 2, Proto Oncogene Tyrosine Protein Kinase Receptor Ret, and Mast/Stem Cell Growth Factor Receptor Kit.
The key mechanisms of action in the Follicular Thyroid Cancer pipeline product include Vascular Endothelial Growth Factor Receptor 2 Inhibitor with five drugs in Phase III. The Follicular Thyroid Cancer pipeline products include six routes of administration with the top ROA being Oral and eight key molecule types in the Follicular Thyroid Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Follicular Thyroid Cancer overview
Follicular thyroid carcinoma is a cancer that forms in follicular cells of the thyroid. Follicular thyroid cancer constitutes 10 to 15% of all thyroid cancer cases, making it the second most common. Unlike differentiated types, undifferentiated types are rare. Diagnosis of follicular thyroid carcinoma relies on pathologic confirmation of follicular cells devoid of the nuclear atypia seen in papillary thyroid cancer, considering factors like capsular and vascular invasion. Evaluation primarily centers on histological findings, with controversy arising due to variations among pathologists. Treatment modalities for follicular thyroid carcinoma hinge on the stage at presentation. Minimally invasive cases undergo thyroid lobectomy and isthmectomy, while invasive cases necessitate total thyroidectomy, radioiodine ablation, and thyrotropin-suppressing medications. Studies highlight a 2.1-fold increase in recurrence for those skipping radioiodine ablation, reinforcing the standard recommendation of total thyroidectomy followed by radioiodine radiation.
For a complete picture of Follicular Thyroid Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
